Novel iNOS homodimerization inhibitor

The first reported PPARα/δ dual antagonist

Novel dual PPARα/γ agonist, ameliorating insulin resistance and gluconeogenesis in vivo and vitro

Novel inhibitor of protein-protein interaction (PPI), blocking #212121; font-family: BlinkMacSystemFont, -apple-system, "Segoe UI", Roboto, Oxygen, Ubuntu, Cantarell, "Fira Sans", "Droid Sans", "Helvetica Neue", sans-serif; font-size: 14px; font-style: no

Novel insulin mimetic

Novel pan-RAS-effector PPI inhibitor

Novel PPK1 inhibitor, preventing UTI effectively through the disruption of the PPK1 function

Novel PPK1 inhibitor, preventing UTI effectively through the disruption of the PPK1 function

Potent and selective antagonist of melanocortin-4 receptor (MC4R)

Novel anti-influenza agent, interrupting the crucial RNP trafficking, resulting in influenza replication inhibition, preventing virus-induced cytopathic effects

Novel Modulator of Water-Heme Interactions in Low-Spin P450 Complexes of CYP2C9d and CYP125A1

Novel inhibitor of budding of mVP40 and eVP40 VLPs, blocking mVP40-795 Nedd4 protein-protein interaction.

Specific blocker of the MARV VP40 PPxY-host Nedd4 interaction and subsequent PPxY-dependent egress of MARV VP40 VLPs.

Novel potent neuroprotectant, inhibiting glutamate-induced cell death, caspase-3 activation, and amyloid β1-42-induced cell death, also suppressing mitogen-activated protein kinase kinase 4 (MKK4) and c-jun N-terminal kinase (JNK) signaling activated by n

Novel inhibitor of IMPDH enzyme

Novel human double minute 2 (HDM2) inhibitor

Quorum sensing modulator as a PqsR antagonist

Pradigastat (LCQ-908) is a potent, selective and orally active diacylglycerol acyltransferase 1 (DGAT1) inhibitor. Pradigastat has anti-obesity and anti-diabetic effects.

Inhibitor of prostaglandin (PG) synthesis

Inverse agonist at alpha-1 adrenergic receptors

Novel inhibitor of checkpoint kinase 1 (CHK1)

Inducer of Functional Neurorestoration Via the Sigma-1 Receptor